Randomized Trialhigh evidence
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
The New England journal of medicine·May 29, 2026·PMID 42212933
Why it mattersTeclistamab offers a highly effective, off-the-shelf immunotherapy option earlier in the treatment course, potentially delaying disease progression and improving survival compared to standard triplet regimens in a population with limited remaining options.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled